Kanin Energy set up shop in Greentown Labs last year to grow its impact on the energy transition. Photo via Getty Images

Waste heat is everywhere, but in Houston, the Energy Capital of the World, it is becoming a hot commodity. What is it? Janice Tran, CEO of Kanin Energy, uses the example of turning ore into steel.

“There’s a lot of heat involved in that chemical process,” she says. “It’s a waste of energy.”

But Kanin Energy can do something about that. Its waste-heat-to-power, or WHP, concept uses a technology called organic rankine cycle. Tran explains that heat drives a turbine that generates electricity.

“It’s a very similar concept to a steam engine,” she says. Tran adds that the best term for what Kanin Energy does is “waste heat recovery.”

Emission-free power should be its own virtuous goal, but for companies creating waste heat, it can be an expensive endeavor both in terms of capital and human resources to work on energy transition solutions. But Kanin Energy helps companies to decarbonize with no cost to them.

“We can pay for the projects, then we pay the customers for that heat. We turn a waste product into a revenue stream for our customer,” Tran explains. Kanin Energy then sells the clean power back to the facility or to the grid, hence decarbonizing the facility gratis. Financing, construction, and operations are all part of the package.

Kanin Energy began at the height of the COVID-19 pandemic, in the spring of 2020.

“We started like a lotus. A lotus grows in mud — you start in the worst conditions and everything is better and easier from there,” says Tran.

That tough birth has helped provide the team with a discipline and thoughtfulness that’s been key to the company’s culture. Remote work has forced the team to get procedures clearly in place and react efficiently.

Back in May of 2020, its inception took place in Calgary. But the team, which also includes CDO Dan Fipke and CTO Jake Bainbridge, began to notice that many of their customers were either based in Houston or had Houston ties.

A year ago, the Kanin team visited Houston to see if the city could be a fit for an office. In July of 2022, Tran opened Kanin Energy offices in Greentown Labs.

“We’re hiring and building our team office out of Greentown. It’s been really great for us,” she says.

With the company now in its commercialization stage, Tran says that becoming part of the Houston energy ecosystem has been invaluable for Kanin.

The investments being made in climate tech and in energy transition make Space City the right place for the company. For Canadian-born Kanin Energy, Houston is now home. Investors across the nation, including Texas, are now helping Kanin to blossom, much like the lotus.

Janice Tran is the CEO and co-founder of Kanin Energy. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”